Advanced search
Add to list

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection

(2005) HUMAN VACCINES. 1(2). p.61-65
Author
Organization
Abstract
The tolerability and immunogenicity of intradermal injections of a candidate HCV vaccine, based on the E1 protein of the hepatitis C virus (HCV), was examined in an exploratory study in healthy volunteers, in subjects with a history of resolved HCV infection, and in patients suffering from therapy-resistant chronic HCV. Sub-epidermal injection of three doses of 4 mu g of non-adjuvanted E1 vaccine induced much weaker humoral and cellular immune responses in healthy subjects and chronic HCV patients than the intramuscular administration of 20 mu g E1 formulated on alum. However, in three subjects who cleared HCV infection, intradermal administration of this low dose of E1 induced rapid and clear anamnestic responses. These data demonstrate that E1-specific immune responses can be induced in resolving HCV infections and that memory (B and T) cells can be restimulated with suboptimal doses of E1 antigen.
Keywords
Hepatitis C, E1 protein, therapeutic vaccine, intradermal, resolved hepatitis C, immune recall, CHRONIC HEPATITIS-C, B-VACCINE, PLUS RIBAVIRIN, E1

Citation

Please use this url to cite or link to this publication:

MLA
Leroux-Roels, Geert, Arsene-Helene Batens, Isabelle Desombere, et al. “Immunogenicity and Tolerability of Intradermal Administration of an HCV E1-based Vaccine Candidate in Healthy Volunteers and Patients with Resolved or Ongoing Chronic HCV Infection.” HUMAN VACCINES 1.2 (2005): 61–65. Print.
APA
Leroux-Roels, G., Batens, A.-H., Desombere, I., Van den Steen, B., Vander Stichele, C., Maertens, G., & Hulstaert, F. (2005). Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. HUMAN VACCINES, 1(2), 61–65.
Chicago author-date
Leroux-Roels, Geert, Arsene-Helene Batens, Isabelle Desombere, Bart Van den Steen, Christine Vander Stichele, Geert Maertens, and Frank Hulstaert. 2005. “Immunogenicity and Tolerability of Intradermal Administration of an HCV E1-based Vaccine Candidate in Healthy Volunteers and Patients with Resolved or Ongoing Chronic HCV Infection.” Human Vaccines 1 (2): 61–65.
Chicago author-date (all authors)
Leroux-Roels, Geert, Arsene-Helene Batens, Isabelle Desombere, Bart Van den Steen, Christine Vander Stichele, Geert Maertens, and Frank Hulstaert. 2005. “Immunogenicity and Tolerability of Intradermal Administration of an HCV E1-based Vaccine Candidate in Healthy Volunteers and Patients with Resolved or Ongoing Chronic HCV Infection.” Human Vaccines 1 (2): 61–65.
Vancouver
1.
Leroux-Roels G, Batens A-H, Desombere I, Van den Steen B, Vander Stichele C, Maertens G, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. HUMAN VACCINES. 2005;1(2):61–5.
IEEE
[1]
G. Leroux-Roels et al., “Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection,” HUMAN VACCINES, vol. 1, no. 2, pp. 61–65, 2005.
@article{334961,
  abstract     = {The tolerability and immunogenicity of intradermal injections of a candidate HCV vaccine, based on the E1 protein of the hepatitis C virus (HCV), was examined in an exploratory study in healthy volunteers, in subjects with a history of resolved HCV infection, and in patients suffering from therapy-resistant chronic HCV. Sub-epidermal injection of three doses of 4 mu g of non-adjuvanted E1 vaccine induced much weaker humoral and cellular immune responses in healthy subjects and chronic HCV patients than the intramuscular administration of 20 mu g E1 formulated on alum. However, in three subjects who cleared HCV infection, intradermal administration of this low dose of E1 induced rapid and clear anamnestic responses. These data demonstrate that E1-specific immune responses can be induced in resolving HCV infections and that memory (B and T) cells can be restimulated with suboptimal doses of E1 antigen.},
  author       = {Leroux-Roels, Geert and Batens, Arsene-Helene and Desombere, Isabelle and Van den Steen, Bart and Vander Stichele, Christine and Maertens, Geert and Hulstaert, Frank},
  issn         = {1554-8600},
  journal      = {HUMAN VACCINES},
  keywords     = {Hepatitis C,E1 protein,therapeutic vaccine,intradermal,resolved hepatitis C,immune recall,CHRONIC HEPATITIS-C,B-VACCINE,PLUS RIBAVIRIN,E1},
  language     = {eng},
  number       = {2},
  pages        = {61--65},
  title        = {Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection},
  url          = {http://dx.doi.org/10.4161/hv.1.2.1554},
  volume       = {1},
  year         = {2005},
}

Altmetric
View in Altmetric
Web of Science
Times cited: